Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
3.205
-0.175 (-5.18%)
Mar 31, 2025, 10:53 AM EDT - Market open
Corvus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Corvus Pharmaceuticals stock have an average target of 12.63, with a low estimate of 3.50 and a high estimate of 21. The average target predicts an increase of 294.07% from the current stock price of 3.21.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Corvus Pharmaceuticals stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $14 → $15 | Buy | Maintains | $14 → $15 | +368.02% | Mar 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +243.21% | Mar 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +243.21% | Jan 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +243.21% | Jan 2, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $8 → $14 | Buy | Reiterates | $8 → $14 | +336.82% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
n/a
from 101.79M
Revenue Next Year
n/a
EPS This Year
-0.50
from -1.02
EPS Next Year
-0.63
from -0.50
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 10.5M | 35.9M | ||
| Avg | n/a | 2.6M | 19.9M | ||
| Low | n/a | n/a | 2.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,308.2% | ||
| Avg | - | - | 679.9% | ||
| Low | - | - | -7.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.46 | -0.43 | -0.35 | ||
| Avg | -0.50 | -0.63 | -0.56 | ||
| Low | -0.55 | -0.78 | -0.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.